IMMUNEONCO-B (01541) has released its interim results for the six months ended June 30, 2026, reporting revenue of RMB 25.424 million. Research and development expenses totaled RMB 155 million, reflecting a year-on-year decrease of 7.9%.

According to the announcement, the revenue during this period was primarily attributable to payments received under the licensing and collaboration agreement entered into with Axion Bio, Inc. in 2024. During the reporting period, the company continued to rapidly advance its drug pipeline development, achieving significant milestones in both oncology immunotherapy and autoimmune disease treatment areas.

Major clinical-stage assets including IMM01 (Tidelasicept), IMM0306 (Amurifusp alfa), and IMM2510 (Poviralimab alfa) have made substantial progress, with multiple key clinical trials reaching critical junctures. Concurrently, the company has been actively expanding into non-oncology therapeutic areas, making notable strides in autoimmune diseases, metabolic disorders, cardiovascular conditions, and pulmonary arterial hypertension, further unlocking the therapeutic potential of its drug candidates.